Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.

A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.

The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.

Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.

Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanoparticles can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapeutic compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed.

Provided herein are kits, compositions, and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a radioisotope, a gelatin matrix and bovine collagen or a thixotropic gel. Another aspect provides methods for treating a disease, disorder, or condition.

The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27.sup.th to 36.sup.th, and after binding with the chelating agent and labeling the radiation nucleus .sup.66Ga.sup.67Ga.sup.68Ga.sup.177Lu or .sup.111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.

The invention provides a compound having the following structure:

T-DOTA-R,

wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.